Literature DB >> 8325334

Variable region sequences of autoantibodies from mice with experimental systemic lupus erythematosus.

A Waisman1, E Mozes.   

Abstract

We have sequenced nine monoclonal antibodies (mAb) derived from C3H.SW mice in which experimental systemic lupus erythematosus (SLE) was induced. The hybridomas were selected for binding to DNA or to HeLa nuclear extract (NE). Three mAb were found to bind DNA, and are shown to exhibit sequence characteristics of pathogenic anti-DNA antibodies. One, mAb 2C4C2, is shown to use a heavy chain V region gene (VH) identical to the VH of anti-DNA mAb isolated from other lupus-prone mice, namely (NZB x NZW)F1. The light chain V region gene (VL) of mAb 2C4C2 is 98% homologous to the VL of another anti-DNA mAb, also isolated from (NZB x NZW)F1 mice. The other two anti-DNA mAb, 5G12-4 and 5G12-6, share 93% of their VH sequences with that of mAb 2C4C2. Six mAb bound proteins of HeLa NE. Four of these six antibodies were found to use the VH124 VH and V-L7 VL. The nine mAb use a total of five VH and four VL germ-line genes, demonstrating that the autoantibodies induced in mice with experimental SLE do not originate from one B cell clone. Three of these nine VH and VL were identical in sequence to germ-line genes, while at least three others had somatic mutations. The latter suggests that the above autoantibodies arise in mice by both usage of existing (pre-immune) B cells, and through an antigen-driven process. Furthermore, it appears that autoantibodies found in mice with experimental SLE use genetic elements similar to those used by mAb that were isolated from mouse strains which develop lupus spontaneously.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325334     DOI: 10.1002/eji.1830230726

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.

Authors:  M Dayan; R Segal; Z Sthoeger; A Waisman; N Brosh; O Elkayam; E Eilat; M Fridkin; E Mozes
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus.

Authors:  E Eilat; M Dayan; H Zinger; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.

Authors:  N Brosh; E Eilat; H Zinger; E Mozes
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

4.  Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.

Authors:  A Waisman; P J Ruiz; E Israeli; E Eilat; S Könen-Waisman; H Zinger; M Dayan; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

5.  A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation.

Authors:  Dror Luger; Molly Dayan; Heidy Zinger; Jian-Ping Liu; Edna Mozes
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

6.  Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.

Authors:  N Mauermann; Z Sthoeger; H Zinger; E Mozes
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

7.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

8.  A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.

Authors:  Amir Sharabi; Molly Dayan; Heidy Zinger; Edna Mozes
Journal:  J Clin Immunol       Date:  2009-09-16       Impact factor: 8.317

9.  Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies.

Authors:  Z M Sthoeger; M Dayan; A Tcherniack; L Green; S Toledo; R Segal; O Elkayam; E Mozes
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.